BR112012004697B8 - método para purificar um polipeptídeo compreendendo uma região ch2/ch3 - Google Patents

método para purificar um polipeptídeo compreendendo uma região ch2/ch3

Info

Publication number
BR112012004697B8
BR112012004697B8 BR112012004697A BR112012004697A BR112012004697B8 BR 112012004697 B8 BR112012004697 B8 BR 112012004697B8 BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 B8 BR112012004697 B8 BR 112012004697B8
Authority
BR
Brazil
Prior art keywords
polypeptide
purifying
region
eluting
protein
Prior art date
Application number
BR112012004697A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012004697B1 (pt
BR112012004697A2 (pt
Inventor
Brown Arick
Nandini Radhamohan Asha
J Dowd Christopher
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012004697(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012004697A2 publication Critical patent/BR112012004697A2/pt
Publication of BR112012004697B1 publication Critical patent/BR112012004697B1/pt
Publication of BR112012004697B8 publication Critical patent/BR112012004697B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012004697A 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3 BR112012004697B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23886709P 2009-09-01 2009-09-01
US61/238,867 2009-09-01
US25343809P 2009-10-20 2009-10-20
US61/253,438 2009-10-20
PCT/US2010/047448 WO2011028753A1 (en) 2009-09-01 2010-09-01 Enhanced protein purification through a modified protein a elution

Publications (3)

Publication Number Publication Date
BR112012004697A2 BR112012004697A2 (pt) 2015-09-08
BR112012004697B1 BR112012004697B1 (pt) 2021-02-09
BR112012004697B8 true BR112012004697B8 (pt) 2021-05-25

Family

ID=43649614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004697A BR112012004697B8 (pt) 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3

Country Status (14)

Country Link
US (3) US9428548B2 (enExample)
EP (2) EP2473617B1 (enExample)
JP (1) JP5787891B2 (enExample)
KR (1) KR101764449B1 (enExample)
CN (2) CN102686738A (enExample)
BR (1) BR112012004697B8 (enExample)
CA (1) CA2772653C (enExample)
ES (1) ES2787234T3 (enExample)
HR (1) HRP20200581T1 (enExample)
MX (1) MX2012002565A (enExample)
PL (1) PL2473617T3 (enExample)
RU (1) RU2571929C2 (enExample)
SI (1) SI2473617T1 (enExample)
WO (1) WO2011028753A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
SI2462158T1 (en) 2009-08-06 2018-04-30 F. Hoffmann-La Roche Ag Method to improve virus removal in protein purification
KR20120065383A (ko) * 2009-09-10 2012-06-20 론자 바이올로직스 피엘씨 폴리펩티드 정제를 위한 방법 및 시스템
HRP20181846T1 (hr) * 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
JP6420756B2 (ja) * 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
JP6182210B2 (ja) 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
ES2735354T3 (es) 2013-03-14 2019-12-18 Emd Millipore Corp Métodos para aumentar la pureza de proteínas utilizando la cromatografía basada en proteína A
RU2016104542A (ru) * 2013-07-12 2017-08-17 Дженентек, Инк. Осуществление оптимизации входных условий ионообменной хроматографии
PL3068417T3 (pl) * 2013-11-15 2024-05-13 F.Hoffmann-La Roche Ag Sposoby inaktywacji wirusów przy użyciu ekologicznych detergentów
DK3116891T3 (da) * 2014-03-10 2020-05-04 Richter Gedeon Nyrt Immunglobulinrensning ved hjælp af forrensningstrin
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112566930A (zh) * 2018-06-19 2021-03-26 百时美施贵宝公司 使用色谱纯化蛋白质的方法
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
AU2021208632A1 (en) * 2020-01-17 2022-08-04 Regeneron Pharmaceuticals, Inc. Hydrophobic interaction chromatography for viral clearance
KR20250011797A (ko) 2023-07-13 2025-01-22 주식회사 녹십자 알부민이 융합된 단백질의 정제방법

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
ATE130850T1 (de) 1989-07-28 1995-12-15 Wako Pure Chem Ind Ltd Fulgimidderivate.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ATE233813T1 (de) 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69405251T2 (de) 1993-12-10 1998-02-05 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
MX9603773A (es) 1994-03-03 1997-07-31 Genentech Inc Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE122004000047I1 (de) 1996-11-27 2005-04-21 Genentech Inc Humanisierte anti-koerper gegen cd11a.
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
RU2145610C1 (ru) 1998-12-09 2000-02-20 Общество с ограниченной ответственностью "Протеиновый контур" Способ очистки рекомбинантного эритропоэтина человека
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
DK1578774T3 (da) * 2002-09-18 2014-02-03 Danisco Us Inc Oprensning af immunoglobuliner
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
EP1693108A1 (en) * 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
KR101431856B1 (ko) * 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
MX368932B (es) * 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
WO2015198451A1 (ja) 2014-06-26 2015-12-30 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
US20220324905A1 (en) 2022-10-13
EP2473617A4 (en) 2014-04-09
ES2787234T3 (es) 2020-10-15
JP5787891B2 (ja) 2015-09-30
CN108409829A (zh) 2018-08-17
CN102686738A (zh) 2012-09-19
US20130041139A1 (en) 2013-02-14
BR112012004697B1 (pt) 2021-02-09
BR112012004697A2 (pt) 2015-09-08
CA2772653A1 (en) 2011-03-10
MX2012002565A (es) 2012-05-29
RU2012112536A (ru) 2013-10-10
RU2571929C2 (ru) 2015-12-27
EP2473617A1 (en) 2012-07-11
CA2772653C (en) 2019-06-25
JP2013503877A (ja) 2013-02-04
SI2473617T1 (sl) 2020-07-31
PL2473617T3 (pl) 2020-06-29
HRP20200581T1 (hr) 2020-07-10
EP2473617B1 (en) 2020-02-26
WO2011028753A1 (en) 2011-03-10
US20220081466A1 (en) 2022-03-17
US9428548B2 (en) 2016-08-30
EP3736338A1 (en) 2020-11-11
KR101764449B1 (ko) 2017-08-02
KR20120106719A (ko) 2012-09-26

Similar Documents

Publication Publication Date Title
BR112012004697B8 (pt) método para purificar um polipeptídeo compreendendo uma região ch2/ch3
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CR20120371A (es) Antagonistas de pcsk9
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR112013021562A2 (pt) anticorpos para cd70
BR112013027224A2 (pt) proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
BRPI0702163A (pt) composições de toner e métodos
DK2139987T5 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
SI3156422T1 (sl) Človeška protitelesa z visoko afiniteto do PCSK9
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
BR112012017051A2 (pt) método para diminuir a imunogenicidade
BR112013000623A2 (pt) purificação de proteína.
TN2014000134A1 (en) Therapeutic peptides
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
FI20110215L (fi) Polttoainepohjaisen ajoituksen sisältävä moottorinohjausjärjestelmä
BRPI0918842A2 (pt) método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
BRPI0919950A2 (pt) método para alijar uma coluna montante com peça de desgaste otimizada
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF